IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Thu, 18th Jun 2020 16:46

Hutchison China MediTech Ltd - Hong Kong -based biopharmaceutical company - Gets Fast Track Designation from US Food & Drug Administration for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer. Initiating a Phase III registration study, known as the Fresco-2 study, in refractory metastatic colorectal cancer in the US, Europe and Japan. Study is expected to start enrolling patients in mid-2020.

Current stock price: 370.00 pence

Year-to-date change: down 7.5%

By Tapan Panchal; tapanpanchal@alliancenews.com

Related Shares

More News

3 May 2024 13:37

UK shareholder meetings calendar - next 7 days

26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal...

5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discover...

2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA...

2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquinti...